Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 12/20 | 0.50 |
| ▸ | EPHA2 | P29317 | 4/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | EED | O75530 | 1/20 | 0.39 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.39 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.39 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.39 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17002544 | 1.00 | PDE4B (0.50) | PDE4BEPHA2ERBB2EPHB4PDE4A | |
| SCHEMBL18310142 | 0.91 | PDE4B (0.51) | PDE4BEPHA2ERBB2EPHB4PDE4A | |
| SCHEMBL16992189 | 0.86 | PDE2A (0.42) | PDE4BPDE4APDE4CPDE4DPDE2A | |
| SCHEMBL17002545 | 0.85 | PDE4B (0.46) | PDE4BEPHA2ERBB2EPHB4PDE4A | |
| SCHEMBL31385973 | 0.84 | KMT2A (0.46) | PDE4BUSP30 | |
| SCHEMBL15109716 | 0.84 | KMT2A (0.46) | PDE4BUSP30 | |
| SCHEMBL15109717 | 0.84 | KMT2A (0.46) | PDE4BUSP30 | |
| SCHEMBL16991970 | 0.82 | PDE4B (0.60) | PDE4BPDE4APDE4CPDE4DSTS | |
| SCHEMBL31510960 | 0.82 | PDE4B (0.49) | PDE4BEPHA2ERBB2EPHB4STS | |
| SCHEMBL16991907 | 0.80 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4DSTS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786524-B2 | Pharmaceutical compounds | SENTINEL ONCOLOGY LIMITED (GB) | 2023-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11786524-B2 | Pharmaceutical compounds | CHKA, CHKB, TNK2 | PDE4B 508/4885EPHA2 690/4885ERBB2 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.